Clinical trial endpoints: Translating clinical data into real life

Although randomised, controlled trials (RCTs) are the gold standard for assessing the efficacy and safety of a new drug, these trials are conducted in ideal conditions in restricted populations.¹This disparity between the idealised environment of an RCT and the ‘real-world’ experience of the patient is exacerbated by the complexity of MS.2